Company brings a world-acclaimed clinician and researcher for the launch of their innovative software for the diagnostic of Parkinson’s Disease.
GAINESVILLE, FL – neuropacsTM, a leading innovator in AI-driven neurological diagnostics, today announced that Dr. Ostrem has accepted to serve on neuropacs’ Board of Clinical Advisors. Dr. Jill Ostrem is a movement disorders neurologist and Division Chief of the UCSF Movement Disorders and Neuromodulation Center and holds the Carlin and Ellen Wiegner Distinguished Professorship of Neurology at the University of California, San Francisco.
She is perhaps best known for her research focused on improving diagnosis, biomarker discovery, experimental therapeutics, and technical innovations in surgery treatments of movement disorders including Parkinson’s disease, dystonia, and essential tremor. Her efforts have led to advancements in the field of deep brain stimulation (DBS)– implanted devices that deliver electrical impulses to treat movement disorders. She also studies innovations in patient care, education, telehealth and improving health care through advanced technologies.
Dr. Ostrem earned her medical degree from the George Washington University. She completed a residency in neurology and a fellowship in movement disorders at the Ronald Reagan UCLA Medical Center. After joining UCSF in 2003, Dr. Ostrem helped establish its internationally recognized clinical, research and training center for the treatment of movement disorders. The center has a long history and expertise in treating Parkinson’s disease and dystonia with DBS. Dr. Ostrem is a member of the American Neurological Association, American Academy of Neurology and International Parkinson and Movement Disorder Society.
“Dr. Ostrem brings unparalleled expertise and forward-thinking insights that will prove critical for the strategic rollout of neuropacs’ Parkinson’s diagnostic tool”, stated Dr. Martin Handfield, neuropacs’ President and CEO. “I’m thrilled to join the neuropacs team. The company has developed breakthrough medical technology to benefit patients stricken with debilitating neurological conditions. Neuropacs AI-enabled technology neuropacs will enable earlier intervention and improved patient outcomes”, commented Dr. Ostrem.
For more information about neuropacsTM and its revolutionary diagnostic solutions, visit neuropacs.com.
About neuropacsTM:
neuropacsTM is a pioneering neurological technology company dedicated to developing innovative AI-driven diagnostics. With a commitment to advancing healthcare through cutting-edge technologies, neuropacsTM remains at the forefront of revolutionizing clinical care standards.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.